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background.We sought to investigate the relationship between diabetes and CD34+ stem cell mobilization in patients with chronic heart failure 
(CHF).
Methods: In a prospective study, we enrolled 82 CHF patients on optimal medical therapy, with NYHA class III heart failure and LVEF<40%. In all 
patients, peripheral blood CD34+ cells were mobilized by G-CSF (5 mcg/kg b.i.d.), and collected via apheresis.CD34+cell count in peripheral venous 
blood was measured prior to apheresis. After apheresis, CD34+cell viability was determined with methylene blue staining. Poor stem cell mobilization 
was defined as peripheral CD34+ count< 20 x 106/L, and diabetes was defined in accordance with current guidelines (fasting glucose ≥7.1 mmol/l 
on at least two separate occasions).
results: Of 82 patients enrolled, 15 (18%) had diabetes (DM Group) and 67 (72%) had normal glucose levels (Controls). The two groups did not 
differ in heart failure etiology (ischemic: 60% in DM Group vs. 48% in Controls, P=0.10), gender (male: 86% vs. 83%; P=0.77), age (53±9 years vs. 
58±7 years, P=0.19)), left ventricular ejection fraction (25.1±6.9% vs. 28.9±7.5%, P=0.10), 6-minute walk test distance (401±103 m vs. 440±117 
m, P=0.25), the presence of chronic kidneydisease (33% vs. 34%, P=0.94), or liver disease (6% vs. 8%; P=0.87). After G-CSF stimulation, we found 
significantly lower CD34+cell count in peripheral venous blood in patients with diabetes (37.8±24.6 x 106 cells/L in DM Group vs. 67.1±50.7 x 
106 cells/L in Controls, P=0.03). Poor stem cell mobilization was present in 5/15 (33%) of patients from the DM Group, but only in 7/67 (10%) in 
Controls (P=0.02). The significnat difference in mobilization can not be attributed to CD34+ cell viability, which was similar between the 2 groups 
(viable cells: 95.3±8.5% in DM Group vs. 96.1±7% in Controls, P=0.73).
conclusions: Diabetes appears to be associated with decreased CD34+ stem cell mobilization in patients with CHF. Further studies are needed to 
define whether impaired cell mobilization in diabetes can be reversed with improved glycemic control or by the use of alternative cell mobilization 
strategies.
